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Abstract. The persistence of parasite-specific cellular hyporesponsiveness after clearance of blood microfilariae
(mf) was studied in 18 individuals who had been treated with a single dose of ivermectin, diethylcarbamazine, or a
combination 2-3 years previously and who had initially cleared their parasitemia. At recruitment into the present
study, 50% were again mf+ and 50% remained mf-. There were no significant differences between the mf+ and
mf- groups in the amount of interferon- g (IFN- g) produced by peripheral blood mononuclear cells in response to
adult or microfilarial antigens, although IFN- g production in response to purified protein derivative was greater in
the mf+ group (geometric mean [gm] = 3,791 pg/ml; P = 0.02) than in the mf- group (gm = 600 pg/ml). These
data suggest that although microfilaremic individuals may temporarily regain the ability to produce IFN- g to parasite
antigens post-treatment, they subsequently revert to a state of hyporesponsiveness to mf-containing antigens that
appears to be independent of the recurrence of microfilaremia and the response to nonparasite antigens.
The clinically asymptomatic microfilariae (mf)-positive
group of Wuchereria bancrofti -infected individuals has been
of particular immunologic interest because of the relatively
sparse inflammatory response seen despite the high intra-
vascular parasite burden. Peripheral blood mononuclear cells
(PBMCs) from the majority of individuals with subclinical
microfilaremia display an inability to proliferate or produce
interferon- g (IFN- g ) to filarial adult, mf, or larval antigens.1-
4 These findings, combined with the elevated polyclonal IgE
and antifilarial IgG4 levels found in these patients, suggests
an alteration in the type 1 helper (Thl)/Th2 balance that may
be mediated in part by interleukin-10 (IL-10).1 Persistence
of antigen5,6 and in utero exposure to microfilariae7 have
been postulated as causes for the alteration of responses, as
have mechanisms of peripheral tolerance such as antigen-
induced apoptosis of parasite-specific T cells.8
Recent studies in lymphatic filariasis have demonstrated
that changes in parasite antigen-specific proliferative re-
sponses and cytokine production may depend on the pres-
ence of active infection as measured by circulating filarial
antigen (CAg) independent of clinical presentation,5,9 with
the absence of CAg being associated with greater antigen-
driven proliferation and production of IL-2 and IFN- g.5 In
addition, although cellular responses to parasite antigens
vary and appear to correlate to a large degree with infection
status, the production of IFN- g in response to nonparasite
antigens and mitogens appears to be independent of the stage
and extent of disease, with PBMCs from infected patients
maintaining a Thl-type response to purified protein deriva-
tive (PPD) in the face of nonresponsiveness to adult worm
antigen.5,10
Chemotherapy of the asymptomatic microfilaremic form
of infection with W. bancrofti, however, markedly alters cel-
lular responses to parasite antigens, with changes in respons-
es to nonparasite antigens being variable. There is, however,
considerable variation among published studies of post-treat-
ment immunologic changes with regard to mode and dura-
tion of treatment, populations studied, geographic locales,
and the time points at which immune responses were as-
sayed. Studies of Bancroftian filariasis in Haiti11,12 and Ma-
layan filariasis in Indonesia13 have demonstrated increased T
cell proliferation to parasite antigen at a variety of timepoints
(3.9-12 months) following treatment with diethylcarbama-
zine (DEC) administered at a dose of 6 mg/kg/day or /week
for 12 doses11 or with ivermectin.12 Of interest, PBMCs from
a population in the Cook Islands infected with W. bancrofti
displayed not only impaired cellular proliferation to Brugia
malayi worm extract at baseline, but ongoing suppression of
proliferation for up to two weeks following treatment with
DEC.14
Sartono and others15 have shown that in addition to T cell
proliferative responses, production of IFN- g in response to
B. malayi crude adult antigen increased significantly one
year after treatment in a study population in Indonesia, an
area endemic for Brugian filariasis; however, patients in this
study were treated with DEC every week for the entire year
prior to reassessment of their cellular responsiveness. Dieth-
ylcarbamazine, in addition to its antifilarial activity, has mea-
surable antifungal and antibacterial properties16 and has been
shown to exert an effect on the response to mf in vitro in-
dependent of the effector cell population.17
Because strategies of single-dose administration of anti-
filarial chemotherapeutic agents (ivermectin or DEC) are be-
coming the norm, the present study was designed to inves-
tigate long-term alterations in cellular responses in previ-
ously microfilaremic individuals who had been treated 2-3
years prior to recruitment with single-dose DEC, ivermectin,
or a combination of the two with an eye toward understand-
ing the long-term immunologic consequences of single-dose
therapy.
P A T I E N T S ,  M A T E R I A L S ,  A N D  M E T H O D S
Patients. The study was carried out at the Government
General Hospital in Madras, India under a protocol approved
by the Institutional Review Board of the National Institute
of Allergy and Infectious Diseases, National Institutes of
Health (Bethesda, MD) and the Ethics Committee of the par-
ticipating institute in Madras. Patients were identified from
a cohort of individuals followed for a prior study of mf clear-
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TABLE 1
Study population*
Mf count/ml
Mf status
2-3 years
Treatment Pretreatment posttreatment CAg status
Negative D 625 0 Negative
Negative S 335 0 Negative
Negative D 520 0 Negative
Negative D 285 0 Negative
Negative D 115 0 Positive
Negative D 208 0 Positive
Negative D 445 0 Positive
Negative D 150 0 N D
Negative D 100 0 ND
Positive D 150 40 Positive
Positive D 240 15 Positive
Positive D 398 6 Positive
Positive S 230 400 Positive
Positive S 105 220 Positive
Positive D 102 200 Positive
Positive N A > 100 150 ND
Positive S 350 90 ND
Positive D 375 41 ND
* Mf = microfilariae; CAg = circulating filarial antigen; D = DEC + ivermectin; S =
DEC or ivermectin; ND = not determined; NA = not available.
FIGURE 1. Microfilarial status as a function of pretreatment levels
in the microfilariae (mf)+ ( n ) and mf- ( l ) groups over the study
period in months. The asterisk indicates statistically significant dif-
ferences between the two groups.
ance after treatment with single-dose ivermectin (400 kg/
kg), single-dose DEC (6 mg/kg), or single-dose combina-
tions of ivermectin and DEC at various doses. From the orig-
inal group, 18 individuals were identified, each of whom had
cleared their mf within the first year following treatment
(Kumaraswami V, unpublished data). Each had been treated
between two and three years prior to the present study, and
all had remained in endemic areas in and around Madras.
Individuals had received no further treatment with antifilarial
drugs and were all healthy by history and physical exami-
nation. Informed consent was obtained from all patients.
Blood collection and treatment. A venous blood sample
was collected in heparin between 9:00 PM and 10:30 PM. One
milliliter was filtered through a 0.2-µm Millipore (Bedford,
MA) filter for assessment of mf counts. These individuals
returned the next morning at 10:00 AM for a second periph-
eral venous blood sample for immunologic studies. These
times were chosen because of the nocturnal periodicity of
W. bancrofti; by 10:00 AM, peripheral blood was expected
to be free of circulating mf in southern India. Blood was
collected in EDTA Vacutainer® tubes (Becton Dickinson,
Franklin Lakes, NJ) and used for flow cytometry studies and
whole blood cell culture. Filtration of blood for mf counts
was done by a single individual who was not involved in
the immunologic studies, and the mf status of each individ-
ual in the study was not disclosed until all data had been
collected. All patients were given a single dose of DEC (6
mg/kg) after the morning blood sample was taken.
togen, while the antigens used were B. malayi crude adult
antigen (BmA, 10 µg/ml), B. malayi male antigen (BmM, 5
µg/ml), B. malayi microfilarial antigen (mf, 1 µg/ml), and
Mycobacterium tuberculosis PPD (10 µg/ml). Supernatants
from the media control wells and the PI-IA-stimulated wells
were collected at 24 hr, while supernatants from media con-
trol wells, BmA, BmM, mf, and PPD wells were collected
at 72 hr. Supematants were stored at -70°C until assayed.
Cytokine analysis. Interleukin-5 and IFN- g were mea-
sured in supernatants obtained from whole blood culture by
an ELISA as described previously.18 Four supernatants could
not be analyzed due to contamination in the plate. Values in
pg/ml were obtained by interpolating from a standard curve;
the sensitivity of the IL-5 and IFN- g assays were 7.8 pg/ml
and 39 pg/ml, respectively.
Circulating filarial antigen assays. Thirteen of 18 plas-
ma samples from patients were assayed quantitatively for the
presence of W. bancrofti CAg using a W. bancrofti antigen
detection kit (TropBio; JCU Biotechnology Pty., Ltd.,
Townsville, Australia).
Statistical analysis. Statistical analyses were performed
using the Mann-Whitney paired test and Spearman rank cor-
relation.
RESULTS
Cell culture. Whole blood (1.5 ml) collected in EDTA Eighteen male patients were identified from the records of
was diluted 1:2 in RPMI 1640 medium (BioWhittaker, Walk- a previous multi-arm treatment study at Government General
ersville, MD) with 10% fetal calf serum, gentamicin (1.6 Hospital, Madras (Kumaraswami V, unpublished data). A
mg/L), 1% HEPES, and 1% L-glutamine, and 200 µl of the summary of previously collected and current parasitologic
resulting solution was placed in each well of a 96-well cell and treatment data is shown in Table 1. All patients had
culture plate (Costar, Cambridge, MA). Wells were set up in pretreatment microfilarial counts that ranged between 100
triplicate for each condition, and a media control in triplicate and 625 parasites/ml, and the groups did not differ in this
was used for each patient on each plate. Phytohemagglutinin regard. All patients initially cleared their circulating mf (Fig-
(PHA) at a concentration of 10 µg/ml was used as the mi- ure 1), and by one year post-treatment, the currently mf+
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BmM Mf
F IGURE 2. Net interferon- g (IFN- g) (A-C) and interleukin-5 (IL-5) (D-F) production in response to Brugia mixed adult antigen (BmA; A
and D), adult male antigen (BmM; B and E), and microfilarial antigen (Mf; C and F). Bach square represents an individual patient, and the
horizontal bars are the geometric means. The shaded symbols indicate circulating filarial antigen (CAg) positivity, open symbols indicate CAg
negativity, and striped symbols indicate those in whom CAg assays were not performed.
group had higher levels of blood mf (geometric mean [gm]
percentage pretreatment = 18.8% versus 4.2%). This differ-
ence was more apparent at the 2-3-year timepoint (P <
0.0001) (Figure 1). Of the 18 individuals in this follow-up
study 2-3 years after initial treatment, nine were mf+ (range
= 6-400 mf/ml), and nine were mf- by filtration of 1 ml
of peripheral blood (Table 1).
In the present study, CAg assays were performed on sam-
ples from the 13 of 18 patients from whom plasma was
available. Of these 13, seven were mf- by filtration; four of
the mf- group were also CAg- and three were CAg+ (Ta-
ble 1). The remaining six were mf+ and CAg+.
The production of IL-S was equivalent between the mf-
and mf+ groups, with very low geometric means in response
to parasite antigens, net production being ~3.4 pg/ml and
3.7 pg/ml to BmA, 4.0 pg/ml and 2.2 pg/ml to BmM, and
1.6 pg/ml and 1.5 pg/ml to Mf antigen in the mf- and mf+
groups, respectively (Figure 2D-F). When the groups were
analyzed by CAg status, there were no significant differences
in amount of IL-5 produced by the mf- CAg- group com-
pared with either the mf- CAg+ group or the mf+ CAg+
group.
The IFN- g response to BmA (mixed female and male),
BmM, and mf antigens did not differ between the groups
(Figure 2A-C). The PBMCs from only two of nine mf-
patients and two of eight mf+ patients responded to BmA
with production of IFN- g (gm = 6.1 pg/ml and 2.3 pg/ml,
respectively). The response to mf antigens was similarly
muted, with only two of nine mf- and three of nine mf+
patients producing IFN- g (gm = 1.7 pg/ml and 4.4 pg/ml,
respectively), while the response to BmM Was much more
pronounced, with six of eight mf- patients (gm = 249.1 pg/
ml) and five of nine mf+ patients (gm = 34.3 pg/ml) pro-
ducing IFN- g. The differences between the mf+ and mf-
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FIGURE 3. Net interferon- g (IFN- g) (A and B) and interleukin-5 (IL-5) (C and D) production in response to phytohemagglutinin (PHA; A
and C) and purified protein derivative (PPD; B and D). Each square represents an individual patient, and the horizontal bars are the geometric
means. The shaded symbols indicate circulating filarial antigen (CAg) positivity, open symbols indicate CAg negativity, and striped symbols
indicate those in whom CAg assays were not performed. mf = microfilariae. The asterisk indicates a statistically significant difference between
the groups.
groups as a whole were not statistically significant; when
broken down by CAg status, the only significant difference
was that the production of IFN- g in response to BmM by
the mf- CAg+ patient was greater than its production by
the mf+ group (P = 0.04).
In contrast to the responses to BmA and mf antigen, mea-
surable IFN- g responses to nonparasite antigen and to mi-
togen were seen in all patients. Production of IFN- g in re-
sponse to PPD (Figure 3B) was significantly greater in the
mf+ group (gm = 3,971 pg/ml; P = 0.02) than in the mf-
group (gm = 600 pg/ml). When broken down by CAg status,
there was significantly less production of PPD-driven IFN-
g by the CAg- mf- group compared with the CAg+ mf+
group (P = 0.02). Production of IL-5 (Figure 3D) in re-
sponse to PPD was seen in more patients and to a greater
degree than that in response to parasite antigen, although
there were no differences between the groups based either
on microfilarial status or on CAg status. Similarly, all pa-
tients who were capable of producing IFN- g and IL-5 to
parasite antigens produced more IFN- g and IL-5 in response
to PHA than to these antigens. There was no statistically
significant difference in PHA responsiveness between the
mf+ and mf- groups (Figure 3). When the data were ana-
lyzed based on CAg status, the only significant difference
was that the mf- CAg+ group produced more IFN- g in
response to PHA (gm = 12,977 pg/ml) than did the mf+
CAg+ group (gm = 3,322 pg/ml; P = 0.03).
DISCUSSION
It is well established that most individuals with clinically
asymptomatic microfilaremia are relatively unresponsive to
adult-l-3 and microfilarial-4 derived parasite antigens as mea-
sured by proliferative responses or production of IFN- g or
IL-2. The reasons for this appear to be multifactorial and
include regulation by IL-10,19-22 genetic background, dura-
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tion and intensity of infection,22 in utero exposure to parasite
antigens,7 and the presence of soluble suppressive parasite
products.23 Each of these mechanisms has been implicated
in skewing the immune response away from the production
of IFN- g and IL-2. By whatever mechanism it occurs, the
skewed response reflects the markedly diminished frequency
of antigen-reactive IFN- g -producing cells rather than an in-
crease in IL-4- and IL-5-producing cells.24
Studies in lymphatic filariasis11-13,14 as well as in schisto-
somiasis25 and in onchocerciasis26-30 have, however, demon-
strated a partial reversal of cellular hyporesponsiveness to
parasite antigens and enhancement of responses to nonpar-
asite antigens following treatment of these infections. Most
of these studies demonstrated an increase in IFN- g and IL-
2 production in a segment of the infected study population
to parasite-specific antigen and mitogen. Although study
conditions and parameters varied widely, these changes ap-
peared to be maintained for six months to one year post-
treatment, but by two years, in at least one study,28 responses
returned to baseline.
Fifty percent of the 18 individuals in the present study
who had cleared their microfilaremia following single-dose
DEC or ivermectin or a combination of the two were found
to be mf+ 2-3 years following treatment. Of interest, two
patients who were mf+ at one year post-treatment were mf-
at the time of the present study (Figure 1 and Table 1); this
is likely reflective of the segment of an infected population
that spontaneously clears infection with W. bancrofti. 31
Of importance, however, regardless of recurrence of in-
fection or CAg status, most of the responses to
mf-containing antigens in the group as a whole were muted,
whereas the responses to PPD and PHA were intact. Indeed,
consistent with earlier findings,3 we found that the mf+ in-
dividuals produced significantly more IFN- g than the mf-
group in response to PPD regardless of antigen status (Figure
3B). In contrast, production of IFN- g to mf-containing an-
tigens (Figure 2) was equivalent but low in the mf- and
mf+ post-treatment groups (also independent of antigen sta-
tus), again suggesting the existence of host factors in the
diminished cellular response displayed to mf containing an-
tigens independent of parasite-derived factors. The relatively
greater amount of IFN- g produced in response to BmM in
both groups (Figure 2) probably reflects the absence of grav-
id female worms with mf in the antigen preparation and
corroborates earlier findings.21
Few patients in either group produced IL-5 in response to
adult or microfilarial antigens (Figure 2), and those who did
produced lower amounts of this cytokine than in response to
PHA. This finding may reflect a lack of antigen-driven IL-
2 production that may be required for optimal IL-5 produc-
tion.32 It may also be a consequence of using whole blood
rather than purified PBMCs, or perhaps a function of length
of exposure (e.g., age) to the parasite, as has been recently
suggested.33
Our data support other studies 5,10,34 indicating that respons-
es to parasite and nonparasite antigens are differentially reg-
ulated in filarial-infected individuals. Even in the absence of
Th1-like responses to parasite antigens, responses to PPD
remained Th1-like, with significant amounts of IFN- g pro-
duced by both the mf- and mf+ groups in response to this
nonparasite antigen.
The results from this study differ somewhat from studies
of Brugian filariasis,15 where the reversal of cellular response
was maintained for periods of up to one year. However, our
study looked at time points 2-3 years after treatment, as-
sessed only cytokine production rather than proliferation,
and used a different DEC regimen with lower total quantities
of DEC. Furthermore, we found that the persistent hypore-
sponsiveness to parasite antigens appeared to be independent
of CAg status, in contrast to the findings of Dimock and
others,5 although the number of CAg+ mf- patients in our
study was low.
In summary, our study shows that 2-3 years after treat-
ment, individuals previously infected with W. bancrofti con-
tinue to display mf-specific cellular hyporesponsiveness re-
gardless of their current mf status. That these patients are
able to maintain a Th1 response to nonparasite antigens au-
gers well for the formulation and implementation of health
and immunization programs in these regions.
The fact that half of our study population reacquired mf
positivity 2-3 years following their initial treatment under-
lines the importance of filariasis control programs and reg-
ular chemotherapy in areas of high disease prevalence. In
the present study, five (62.5%) of eight mf+ patients had
been treated with combination single-dose therapy, while
89% (8 of 9) of the mf- group were treated with combi-
nation therapy. This would suggest that although a single-
dose of either drug appears to be completely effective in
initial microfilarial clearance,35-37 the combination of iver-
mectin and DEC is more effective for long-term suppression
of microfilaremia or cure.38 Therefore, as has been pro-
posed,39 implementation of yearly single-dose therapy with
DEC and/or ivermectin would be indicated to establish and
maintain a decrease in the reservoir of infection.
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